ReviewAnnals of medicine2025
Irisin-Treg crosstalk: unveiling a mechanism in neural cognitive regulation.
Review in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIrisin, an exercise-induced myokine, has emerged as a significant player in neural cognitive functions by interacting with regulatory T cells (Tregs). This review synthesizes the expanding research landscape focused on the Irisin-Treg axis, uncovering its critical role in modulating Treg dynamics and neural immune interactions.
methodsA comprehensive review of the literature was conducted to explore how Irisin promotes Treg proliferation and differentiation, and fine-tunes immune responses essential for maintaining neural integrity and function. The review also examines Irisin's neuroprotective properties and its potential as a therapeutic agent.
resultsIrisin enhances Treg-mediated immune regulation, thereby influencing cognitive processes by attenuating inflammation associated with neurodegenerative disorders. It also directly promotes neuronal growth and synaptic plasticity by upregulating neurotrophic factors such as brain-derived neurotrophic factor (BDNF). Collectively, these actions mitigate neuroinflammation and improve neurocognitive function. However, the precise molecular interactions between Irisin and Tregs in brain function remain a subject of debate.
conclusionsThe Irisin-Treg relationship holds promise as an innovative therapeutic target for neurocognitive disorders. Future studies are needed to further elucidate the molecular mechanisms underlying their interaction and to rigorously evaluate the therapeutic efficacy and safety of Irisin-Treg targeted therapies. This review underscores the potential for novel treatment paradigms that could revolutionize the management of neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.